

AWARD NUMBER: W81XWH-13-2-0091

TITLE: Mechanistic Links Between PARP, NAD, and Brain Inflammation After TBI

PRINCIPAL INVESTIGATOR: Raymond A. Swanson, M.D

CONTRACTING ORGANIZATION: Northern California Institute for Research & Education
San Francisco, CA 94121

REPORT DATE: October 2015

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE October 2015		2. REPORT TYPE Annual (year 2)		3. DATES COVERED 25 Sep 2014 - 24 Sep 2015	
4. TITLE AND SUBTITLE Mechanistic Links Between PARP, NAD, and Brain Inflammation After TBI				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-13-2-0091	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Raymond A. Swanson, MD E-Mail: Raymond.swanson@va.gov				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) NCIRE 151NC, 4150 Clement St. San Francisco, CA 94121				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT This project is a pre-clinical evaluation of the efficacy of veliparib and NAD as agents for suppressing inflammation and improving outcomes after traumatic brain injury. The animal models include pig and rat models of controlled cortical impact and blast injury. Work completed in this year 2 (of 3) includes the large majority of the pig CCI and blast studies, and all rat veliparib animal surgeries. The behavioral analyses for these is completed, and the histological analyses are ongoing. Rat blast studies are ongoing. The studies using NAD as an anti-inflammatory agent have also been initiated. Results of the studies completed confirm that veliparib and NAD attenuate microglial activation after both blast and CCI. Veliparib improves outcome on some of the elevated plus maze and several aspects of the 5-choice reaction test when administered within 2 hours of injury. Analysis of long term (2-month) survival is ongoing. .					
15. SUBJECT TERMS brain injury, blast injury, rat, pig, inflammation, metabolism, microglia					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 18	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
1. Introduction.....	4
2. Keywords.....	4
3. Accomplishments.....	4
4. Impact.....	6
5. Changes/Problems.....	6
6. Products.....	7
7. Participants & Other Collaborating Organizations.....	7
8. Special Reporting Requirements.....	n/a
9. Appendices.....	9

1. INTRODUCTION

This is a pre-clinical study to establish the effectiveness of two anti-inflammatory approaches in improving recovery after traumatic brain injury. The studies employ rats and pigs, and use blast injury and controlled cortical injury (CCI) models. The underlying rationale for these studies is based on the salutary effects of ketogenic diet, which acts in part by suppressing brain inflammatory responses. Here we aim to suppress inflammation with (a) veliparib (an inhibitor of poly(ADP-ribose) polymerase, which acts by suppressing NF-kB – mediated inflammatory responses; and (b) intranasal NAD, a natural metabolite which we have in prior studies shown to also suppress poly(ADP-ribose) polymerase activity and inflammatory responses. CtBP1/2 knockout mice will be generated to test a specific mechanism by which ketogenic diet could may have anti-inflammatory effects. For all studies, outcome measures include histological indices of inflammation, cell death, and axonal injury, with behavioral indices of motor coordination, cognitive function, and anxiety. Some studies also use electrocorticography measures of brain network activity.

2. KEYWORDS

brain injury, blast injury, mouse, rat, pig, electrocorticography, inflammation, metabolism, microglia, ketogenic diet

3. ACCOMPLISHMENTS

What were the major goals of the project?

From the SOW:

Year 1

a) Establish blast injury models for rats and swine.

Status: Completed.

b) Initiate blast injury studies in rats and swine

Status: Completed

c1) In rats, establish the dose and time window of opportunity' for treatment with a PARP inhibitor (veliparib).

Status: Surgery and behavioral outcome studies completed (see Appendix D, E, and F); analysis of histological data is ongoing

c2) In rats, establish the 'time window of opportunity' for treatment with intranasal NAD .

Status: Analysis of histological outcomes at the early time point (15 minutes) is ongoing. Studies at later time points have not yet been initiated.

d) In pigs, establish the time window of opportunity for treatment with a PARP inhibitor.

Status: Completed (though this aim was truncated to histological analysis at a single time point as described previously.)

Year-2:

a1) In rats, establish the efficacy and ‘time window of opportunity’ for veliparib treatment after blast injury, using histological and behavioral outcome measures

Status: Behavioral analysis at the early time point is completed (see Appendix E)

a2) In rats, establish the efficacy and ‘time window of opportunity’ for NAD treatment after blast injury, using histological and behavioral outcome measures

Status: Histological analysis at the earlier time point is ongoing.

b) In pigs, establish the efficacy and ‘time window of opportunity’ for veliparib treatment after blast injury, using histological and behavioral outcome measures.

Status: Completed (blast injury produced no consistent histological injury)

c) In rats, identify the electrophysiological changes in motor circuit function after CCI during over the acute and recovery periods using cortical and depth electrode arrays.

Status: Studies are ongoing

d) Using a CtBP1/2 transgenic mouse, test the hypothesis that effects of a ketogenic diet can be replicated by inhibiting CtBP dimerization.

Status: There have been problems in generating the mouse (see below). We have proof of principle for this idea using a peptide inhibitor.

What opportunities for training and professional development has the project provided?

1. Two members of the research team attended the 2015 California Neurotrauma symposium (Won and Bishop)
2. Three members of the research team attended the Society for Neuroscience Meeting and presented the work described here (Swanson, Won, and Irvine)
3. The P.I. was a participant in the Dept. of Veterans Affairs State of the Art conference on traumatic brain injury .

How were the results disseminated to communities of interest?

- 1.) Poster presentation at the 2015 Society for Neuroscience Meeting (see appendix)

What do you plan to do during the next reporting period to accomplish the goals?

Studies will proceed as described in the award proposal/SOW. In particular, we will proceed to studies involving behavioral outcome measures and the electrocorticography measures, and studies with the CtBP mouse.

4. IMPACT

What was the impact on the development of the principal discipline(s) of the project?

Nothing to Report

What was the impact on other disciplines?

Nothing to Report

What was the impact on technology transfer?

Nothing to Report

What was the impact on society beyond science and technology?

Nothing to Report

5. CHANGES/PROBLEMS

Changes in approach and reasons for change.

1. Pig behavioral studies – showed no behavioral deficits after either blast or CCI. Our evaluations included a novel object recognition task, a hurdle crossing tasks, and a video analysis of gait. Discussion of this issue with other researchers in the field identifies this as a major limitation with use of pigs in general, stemming from their proclivities as herd animals, lack of digits, and small numbers available for any given experiment. We have discontinued the pig behavioral experiments and will use only histological outcome measures from the pigs.

2. Rat blast model - showed little blast-induced injury when the head is fully immobilized. There was a reproducible signal on some of the behavioral studies, which is interesting in itself, but as a criteria for evaluation of NAD and veliparib this is insufficient. We have revised the blast studies to allow reproducible head movement in one direction. This is thus a more complex model – involving both blast and closed head trauma – but it is on the other hand much more realistic than a “pure” blast exposure.

3. Constructs for generating conditional CtBP2^{-/-} mice were sequenced and found to be correct, but 2 attempts at generating ES cells from these constructs failed. We have therefore proceeded with the new TALENS system for generating the mice.

Changes that had a significant impact on expenditures. None

Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents. None

Significant changes in use or care of human subjects. N/A

Significant changes in use or care of vertebrate animals. None

Significant changes in use of biohazards and/or select agents. N/A

6. PRODUCTS

Journal & book publications. None

Other publications, conference papers, and presentations.

See Appendix C. Presentation at 2015 Society for Neuroscience meeting

Website(s) or other Internet site(s). None.

Technologies or techniques. None.

Inventions, patent applications, and/or licenses. None

Other Products. None

7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

What individuals have worked on the project?

Name:	Raymond A. Swanson MD
Project Role:	PI
Researcher Identifier	ORCID 0000-0002-3664-5359
Nearest person month worked	2.4
Contribution to project	Study design, personnel recruitment, compliance, data analysis
Funding support	This award

Name:	S. Scott Panter PhD
Project Role:	Faculty
Researcher Identifier	
Nearest person month worked	1.0
Contribution to project	Supervision of all studies done with pigs
Funding support	This award, Dept. of Veterans Affairs

Name:	Karunesh Ganguly, MD, PhD
Project Role:	Faculty
Researcher Identifier	
Nearest person month worked	1.5
Contribution to project	Mouse electrocorticography studies
Funding support	Dept. Veterans Affairs

Name:	Valerie Coppes
Project Role:	Large animal surgery technician
Researcher Identifier	

Nearest person month worked	3.0
Contribution to project	Conducted pig TBI and histology
Funding support	Dept. Veterans Affairs

Name:	David Kapfhamer, PhD
Project Role:	Research Scientist
Researcher Identifier	
Nearest person month worked	8.0
Contribution to project	Rat histology and behavioral assessments
Funding support	This award

Name:	Katherine Hamel
Project Role:	Large animal surgery technician
Researcher Identifier	
Nearest person month worked	6
Contribution to project	Pig TBI, post-op monitoring, and histology
Funding support	This award

Name:	Seok Joon Won, Robin Bishop, PhD
Project Role:	Research Scientist
Researcher Identifier	
Nearest person month worked	9.0
Contribution to project	
Funding support	This award

Name:	Karen-Amanda Irvine, PhD
Project Role:	Research Scientist
Researcher Identifier	
Nearest person month worked	12.0
Contribution to project	Rat behavioral studies and rat brain histology
Funding support	This award

Name:	Robin Bishop, MS
Project Role:	Technician / Lab supervisor
Researcher Identifier	
Nearest person month worked	9.0

Contribution to project	Purchasing, stocking, coordinates studies, assists in behavioral assessments, conducts rat blast injury experiments.
Funding support	This award

Change in active other support of the PD/PIs or senior /key personnel

Dr. Panter has retired due to health reasons and as of May 2015 is no longer receiving support through this grant. Support to Valerie Coppes, Katherine Hamel, has also ended, and support to David Kapfhamer will end 11/15/15.

What other organizations were involved as partners?

None

8. SPECIAL REPORTING REQUIREMENTS

Not applicable

9. APPENDICES

Appendix A. Updated Quad Chart

Appendix B. Presentation at University of California Traumatic Brain Injury conference

Appendix C. Presentation at 2015 Society for Neuroscience meeting

Appendix D. Rat behavioral data summaries

Appendix E. Dose response veliparib summary

Appendix F. Gene expression changes after rat CCI

APPENDIX A

Mechanistic Links between PARP, NAD, and Brain Inflammation after TBI

Log Number 13306001

Award Number W81XWH-13-2-0091

PI: Raymond A. Swanson, M.D.

Org: Northern California Institute for Research and Education

Award Amount: \$1,979,662

Study/Product Aim(s)


Objective: Establish a validated treatment approach for TBI, targeting brain inflammation, that can be implemented hours-to-days after injury.

Aims:

- Evaluate functional and histological markers of focal injury and diffuse axonal injury.
- Evaluate the effects of a PARP inhibitor (veliparib) on these endpoints
- Evaluate delayed intranasal administration of NAD on these endpoints
- Test the hypothesis that the effects of intranasal NAD and ketogenic diet on TBI are each mediated through actions of the NAD-sensitive transcription factor, CtBP, on inflammatory pathways.

Approach

Studies employ two TBI models: blast injury and controlled cortical impact, and 2 species, rat and pig. Animals are treated post-injury with veliparib or NAD, and subsequently assessed by behavioral tests (for anxiety, learning, and motor function) and histological measures (for inflammation, cell death, and axonal injury).



Accomplishment: Veliparib 3 mg/kg/d was shown to completely suppress microglial activation after TBI, in both rats and pigs.

Timeline and Cost

Activities	CY 13	14	15	16
Establish the TBI models & histological and behavioral outcomes				
Evaluate veliparib in these models				
Evaluate NAD in these models				
Identify e-phys correlates of recovery and drug effects				
Generate CtBP1/2 ko mouse				
Estimated Budget (\$K)	238	635	635	475

Updated: October 24, 2015

Goals/Milestones

CY13 Goal – Equipment acquisition, personnel hires, and approvals

☒ All in place

CY14 Goals – Model characterizations (behavioral and histological)

☒ Rat CCI ☒ Rat blast ☒ Pig CCI ☒ Pig blast

☒ Dose / response of veliparib on brain inflammatory response

CY15 Goal – Establish veliparib efficacy at delayed time points after TBI

☒ Rat CCI ☐ Rat blast

CY16 Goals – Establish NAD efficacy at delayed time points after TBI

☒ Dose / response of NAD on brain inflammatory response

☐ Evaluate e-phys effects of veliparib & NAD

☐ Evaluate CtBP^{-/-} genotype on TBI outcomes

Comments/Challenges/Issues/Concerns

*. CtBP ko mouse still in production

* Behavioral studies in the pig are not feasible

Budget Expenditure to Date

Projected Expenditure: \$1,508,000

Actual Expenditure: \$1,668,355

APPENDIX B

Oral Presentation to 2014 University of California Brain Trauma meeting



True Blast injury – Fact or Fiction?

DoD- funded project to evaluate effectiveness of using a PARP inhibitor (veliparib) to suppress brain inflammation after TBI in multiple preclinical models:

- CCI and blast injury in rats (Raymond Swanson, Robin Bishop, Seok Joon Won)
- CCI and blast injury in swine (Scott Panter, Valerie Coppes, Katie Hamel, Preeti Mann)

Blast exposure (e.g. land mine, or mortar shell) → multiple mechanisms of brain injury

- Skull penetration
- Brain deformation due to rapid acceleration/deceleration
- Brain vs. skull collision
- Intrinsic effects of a blast wave on axons, capillaries, etc.

Does this mechanism in fact contribute to brain injury?

The technical, experimental issue:
Experimental blast exposure also causes head movement / skull deformation.

This study:
Compare histologic outcomes after blast exposure to rats with some head movement vs. “no” head movement.

Blast Tube setup (L-3/Jaycor)

Peak pressure = 220 psi pressure
Positive pressure duration = 2.6 msec





Rotational movement (only)

No head movement

Examples of neuronal injury induced by 3 different grades of blast injury in cortex (left) and hippocampus (right). The highest grade, 15 mil, corresponds to 200 psi overpressure. Dead neurons are stained bright green by fluoro-jade B

At 1 day after blast

At 3 day after blast





Introduction

Traumatic brain injury (TBI) is a major cause of long-term disability in traumatized and developing countries across the world (Lynch 2003). TBI leads to tissue disruption and release of myelin basic protein and axonal debris that elicit microglial activation and subsequent release of proinflammatory cytokines and chemokines. Microglial activation is characterized by morphological changes, including loss of ramification and increased expression of markers such as CD11b, IBA1, and CD68. Microglial activation is also associated with increased production of reactive oxygen and nitrogen species, which can lead to neuronal damage and cell death. Microglial activation is a key component of the inflammatory response to TBI and is associated with poor outcomes. Therefore, understanding the mechanisms of microglial activation and identifying potential therapeutic targets to suppress microglial activation are critical for improving outcomes in TBI.




Figure 1: Schematic diagram of the experimental protocols used in the study. Veliparib (3mg/kg) was administered to rats and pigs 3 days post-injury. The diagram shows the timeline of the study, including the injury, the treatment, and the assessment of microglial activation.




Figure 2: (A) Representative images of the ventral immunohistochemical staining for IBA1 and GFAP in the brain tissue of Sham, CCI, and Veliparib groups. (B) Quantitative analysis of IBA1 and GFAP staining. The bar graph shows the mean intensity of IBA1 and GFAP staining in the Sham, CCI, and Veliparib groups. The Sham group shows low intensity, while the CCI group shows high intensity. The Veliparib group shows significantly reduced intensity compared to the CCI group.








Figure 3: Preliminary behavioral studies indicate a beneficial effect of Veliparib on functional outcome that is dependent on timing of drug treatment.





Figure 3: (A) Schematic diagram of the experimental protocols used in the study. (B) Representative images of the ventral immunohistochemical staining for IBA1 and GFAP in the brain tissue of Sham, CCI, and Veliparib groups. (C) Quantitative analysis of IBA1 and GFAP staining. The bar graph shows the mean intensity of IBA1 and GFAP staining in the Sham, CCI, and Veliparib groups. The Sham group shows low intensity, while the CCI group shows high intensity. The Veliparib group shows significantly reduced intensity compared to the CCI group.

Figure 3: (A) Schematic diagram of the experimental protocols used in the study. (B) Representative images of the ventral immunohistochemical staining for IBA1 and GFAP in the brain tissue of Sham, CCI, and Veliparib groups. (C) Quantitative analysis of IBA1 and GFAP staining. The bar graph shows the mean intensity of IBA1 and GFAP staining in the Sham, CCI, and Veliparib groups. The Sham group shows low intensity, while the CCI group shows high intensity. The Veliparib group shows significantly reduced intensity compared to the CCI group.


APPENDIX D




----- = Half way point
(guide only)





COMBINING COHORTS 2 AND 4 (VELIPARIB DRUG TRIALS)










COMBINING COHORTS 1 AND 3 (BLAST TRIALS)






APPENDIX E



APPENDIX F



Gene expression in lesioned cortex after CCI in the rat



Effects of veliparib on gene expression at day 3 after CCI